Fevipiprant
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Unaffected by food[1] |
| Metabolism | Hepatic glucuronidation |
| Biological half-life | ~20 hours |
| Excretion | Renal (≤30%) |
| Identifiers | |
| |
| CAS Number | 872365-14-5 |
| PubChem (CID) | 23582412 |
| ChemSpider | 23582412 |
| UNII | 2PEX5N7DQ4 |
| KEGG | D10631 |
| Chemical and physical data | |
| Formula | C19H17F3N2O4S |
| Molar mass | 426.41 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).[1][2][3]
As of 2016, it is in Phase III[4] clinical trials for the treatment of asthma.[5]
See also
References
- 1 2 Erpenbeck VJ, Vets E, Gheyle L, Osuntokun W, Larbig M, Neelakantham S; et al. (2016). "Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers". Clin Pharmacol Drug Dev. 5 (4): 306–13. doi:10.1002/cpdd.244. PMID 27310331.
- ↑ Sykes DA, Bradley ME, Riddy DM, Willard E, Reilly J, Miah A, Bauer C, Watson SJ, Sandham DA, Dubois G, Charlton SJ. Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy. Mol Pharmacol. 2016 May;89(5):593-605. doi: 10.1124/mol.115.101832 PMID 26916831
- ↑ Erpenbeck VJ, Popov TA, Miller D, Weinstein SF, Spector S, Magnusson B; et al. (2016). "The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma". Pulm Pharmacol Ther. 39: 54–63. doi:10.1016/j.pupt.2016.06.005. PMID 27354118.
- ↑ https://clinicaltrials.gov/ct2/show/NCT02555683
- ↑ Gonem S, Berair R, Singapuri A, Hartley R, Laurencin M, Bacher G; et al. (2016). "Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial". Lancet Respir Med. doi:10.1016/S2213-2600(16)30179-5.
This article is issued from Wikipedia - version of the 11/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.